NKTR241220P500
- 0.00
- 0.000.00%
Nektar Therapeutics Newsroom
Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem
B-cell Lymphoma Pipeline Insight 2024, With Comprehensive Insights for 295+ Companies and 300+ Pipeline Drugs - ResearchAndMarkets.com
Insider Sale: Chief R&D Officer of $NKTR (NKTR) Sells 7,785 Shares
Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic...
Getting In Cheap On Nektar Therapeutics (NASDAQ:NKTR) Is Unlikely
Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nektar Therapeutics To Present At UBS Global Healthcare Conference; Webcast At 1:15 PM ET
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets
Nektar Therapeutics | 10-Q: Q3 2024 Earnings Report
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript Summary
Nektar Therapeutics | 8-K: Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Posts Q3 Revenue $24.1M
Nektar Therapeutics GAAP EPS of -$0.18 Beats by $0.03, Revenue of $24.12M Beats by $5.84M
Express News | Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Express News | Nektar Therapeutics Q3 Income From Operations USD -34.345 Million
Press Release: Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Nektar Therapeutics 3Q Loss/Shr 18c >NKTR
Nektar Therapeutics Q3 24 Earnings Conference Call At 5:00 PM ET